1.21
Precedente Chiudi:
$1.16
Aprire:
$1.15
Volume 24 ore:
1.08M
Relative Volume:
1.74
Capitalizzazione di mercato:
$18.40M
Reddito:
$486.00K
Utile/perdita netta:
$-28.43M
Rapporto P/E:
-0.4292
EPS:
-2.8189
Flusso di cassa netto:
$-26.75M
1 W Prestazione:
-9.02%
1M Prestazione:
+35.96%
6M Prestazione:
-56.32%
1 anno Prestazione:
-43.19%
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Nome
Vyne Therapeutics Inc
Settore
Industria
Telefono
800-775-7936
Indirizzo
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Confronta VYNE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VYNE
Vyne Therapeutics Inc
|
1.21 | 22.16M | 486.00K | -28.43M | -26.75M | -2.8189 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-18 | Iniziato | BTIG Research | Buy |
2021-12-06 | Ripresa | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Borsa (VYNE) Ultime notizie
Is VYNE Therapeutics Inc. a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com
What drives VYNE Therapeutics Inc. stock priceConsistently profitable trades - Autocar Professional
What analysts say about VYNE Therapeutics Inc. stockSuperior portfolio returns - Autocar Professional
VYNE Therapeutics Inc. Stock Analysis and ForecastSuperior profit margins - jammulinksnews.com
Does VYNE Therapeutics Inc. stock pay reliable dividendsFree Capital Allocation Plans - Newser
How VYNE Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser
Why VYNE Therapeutics Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
What makes VYNE Therapeutics Inc. stock price move sharplyIntraday Trade Ideas - Newser
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress - MSN
VYNE Therapeutics: A High-Stakes Gamble on Vitiligo and Psoriasis - AInvest
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% – Should You Sell? - Defense World
VYNE Unblinds Early VYN202 Data After Safety Pause - Dermatology Times
BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data - Investing.com Canada
H.C. Wainwright reiterates Buy rating on VYNE Therapeutics stock amid clinical hold update - Investing.com Canada
NOVT secures new $1B credit facility, extends maturity to 2030 | VYNE SEC FilingForm 4 - Stock Titan
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - The Manila Times
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | VYNE Stock News - GuruFocus
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14% - Nasdaq
Celebrating World Vitiligo Day 2025 with Dermatology Times - Dermatology Times
Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 46.8% - Defense World
Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
Northern Trust Corp Has $80,000 Stock Holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges By Investing.com - Investing.com South Africa
VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India
VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $1.17 Amid Market Challenges - Investing.com
VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Vyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
VYNE Therapeutics Inc Q1 2025 Earnings: EPS of -$0.20 Beats Estimate, Revenue of $0.2 Million Exceeds Forecast - GuruFocus
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - The Manila Times
Renaissance Technologies LLC Decreases Stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Therapeutics Inc (VYNE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Closing Strong: VYNE Therapeutics Inc (VYNE) Ends at 1.43, Down -23.94 from Last Close - DWinneX
Market Watch: Renovaro Inc (RENB)’s Noteworthy Gain, Closing at 0.37 - DWinneX
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Vyne Therapeutics Inc Azioni (VYNE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):